mTORC1 Inhibition Platform

Navitor’s proprietary NAValogs have the potential to ‘turn down’ over-activation of the mTORC1 pathway in chronic diseases, such as Chronic Kidney Disease.

They may also have application in progressive diseases, such as Alzheimer’s, Parkinson’s, Huntington’s and other neurodegenerative diseases that involve abnormal protein folding, possibly due to excessive and unrestrained protein synthesis.

Back to Top